We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.
6 hours ago | Petitionbuzz
The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention. See http://eatgavacprevention.tumblr.com for more. In addition to comprehensive updates on product pipelines across the prevention research landscape, the group discussed the anticipation of the first data from European oral PrEP trials and the implications for PrEP access in Europe.
28 January 2015 | AVAC
New intellectual property ‘think tank’ draft policy already showing alarming trend.
23 January 2015 | Medecins Sans Frontieres press release
Europe is to become the next battleground between Gilead Sciences and AbbVie in their scramble to win share of the fast-growing market for hepatitis C drugs. The companies have been fighting a high-profile price war in the US over a new generation of blockbuster medicines that can cure most people with the virus within weeks. The pair are preparing to open a new front across the Atlantic after European regulators gave AbbVie’s hepatitis C treatment the green light on Friday.
20 January 2015 | Financial Times (free registration required)
The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.
19 January 2015 | AllAfrica
The latest issue of the Global Fund News Flash discusses the importance of dialogue and cooperation for achieving global health goals; reaching key populations with HIV prevention, treatment, and care services; and preventing malaria in Myanmar.
19 January 2015 | The Global Fund
Gilead has announced both the highest recorded prices ever for its direct acting hepatitis C antiviral, ledipasvir/sofosbuvir (Harvoni), and one of the most stringent anti-diversion programs ever devised. The price, highest in the U.S., comes in at a whopping US$94,000 for a 12-week course of treatment, with slightly lower prices in Europe.
19 January 2015 | The Body Pro
The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.
16 January 2015 | The Guardian
In June of 2014, New York's Governor Andrew Cuomo committed to the NYS Plan to End AIDS. The plan offers great hope and makes HIV once again an important public health priority. But phrases like "the end of AIDS" must be met with pause. To have any chance of success, any plan will require major efforts by multiple sectors of society.
08 January 2015 | The Body
Reports of sex workers misusing HIV drugs have left activists wondering if the government invested enough in HIV education before purchasing medicine, worth 4 billion Kenyan shilling. Many sex workers say clients prefer to have unprotected sex and will pay more money for it. This being a business, the women often choose to have unprotected sex, then rush to a public hospital for post-exposure prophylaxis medication, claiming they have been raped or had a burst condom. Some sex workers have also expressed uncertainties about the sustainability of the project, so they go to different hospitals and stockpile the medication, just in case it is no longer available in public hospitals.
07 January 2015 | Key Correspondents